Contact : Mr.Thyen
Email us at firstname.lastname@example.org
Whatsapp : +86 180 3817 6818
CAS Registry Number
552.2°C at 760 mmHg
3.07E-12mmHg at 25°C
Drospirenone is one of several different progestins that are used in birth control pills. Most birth control pills (combination oral contraceptives) combine a synthetic version of the female hormone progesterone (referred to as a progestin) with a synthetic version of the female hormone estrogen. In addition to prevention of pregnancy, some birth control pills containing drospirenone are also approved to treat symptoms of premenstrual dysphoric disorder (PMDD), to treat moderate acne, and to raise folate levels, in women who choose to use an oral contraceptive for birth control.
Drospirenone (INN, USAN), also known as 1,2-dihydrospirorenone, is a synthetic hormone used in birth control pills and postmenopausal hormone replacement therapy pills. All of which are combination products of drospirenone with an estrogen such as ethinylestradiol or estradiol.
White or almost white power
Almost white power
1. Specific rotation
Loss on drying
Unspecified impurity <0.10%
Drospirenone Medical uses
Drospirenone is an ingredient in some birth control pills and hormone replacement therapy. In combination with ethinylestradiol it is used as contraception, and for women who want contraception it is also approved by the U.S. Food and Drug Administration (FDA) to treat moderate acne and premenstrual dysphoric disorder.
Drospirenone is 8–10 times more potent as an antimineralocorticoid relative to spironolactone (3 mg drospirenone is equivalent to about 20–25 mg spironolactone in this regard. It is more potent as an antiandrogen relative to spironolactone also but is less potent relative to cyproterone acetate, having about one-third the potency of this drug. Progestogenic, antimineralocorticoid, and mild antiandrogenic effects have been observed in humans during treatment with drospirenone at a dosage range of 0.5 to 4 mg per day orally. The antimineralocorticoid properties exhibited by drospirenone promote sodium excretion and prevent water retention.
Drospirenone is an aldosterone antagonist with potassium-sparing properties, though in most cases no increase of potassium levels is to be expected. In women with mild or moderate renal insufficiency, or in combination with chronic daily use of other potassium-sparing medications (ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, heparin, aldosterone antagonists, or NSAIDs), a potassium level should be checked after two weeks of use to test for hyperkalemia. In addition to contraindications common to all combined estrogen-progestin medications, drospirenone-containing medications are contraindicated in women with severe renal insufficiency according to European Medicines Agency (EMA)-approved labels, and contraindicated in women with renal insufficiency, adrenal insufficiency, or liver disease according to FDA-approved labels.
Women who take contraceptive pills containing drospirenone have a six- to sevenfold risk of developing thromboembolism (dangerous blood clots) compared to women who do not take any contraceptive pill, and have twice the risk (some epidemiological studies suggest thrice, according to the FDA) compared to women who take a contraceptive pill containing levonorgestrel, though the actual risk is small, in the neighborhood of 9 to 27 out of 10,000 women on an oral contraceptive for a year (up to 9 for levonorgestrel vs up to 27 for drospirenone, or about 0.09% vs 0.3% per year.)
While all oral contraceptives can increase the risk for venous thrombembolic events, including fatal blood clots, several studies have reported a greater risk for women taking contraceptives containing drospirenone. (Before becoming alarmed at the huge "relative" differences in risk, one must remember that the "actual" risks involved are quite small — in the neighborhood of 1 in 10,000 to 27 in 10,000 in a year).
When the U.S. Food and Drug Administration (FDA) became concerned about the risks of drospirenone, they funded studies based on the medical records of more than 800,000 women taking oral contraceptives. They found that the risk of VTE, which includes dangerous and potentially fatal blood clots, was 93% higher for women who had been taking oral contraceptives made with drospirenone for only 3 months or less and 290% higher for women taking drospirenone oral contraceptives for 7–12 months, compared to women taking other types of oral contraceptives. To determine the exact risk for women of different ages and different circumstances, further study is warranted.
The FDA recently updated the label for contraceptives containing drospirenone to include warnings for stopping use prior to and after surgery, and to warn that contraceptives with drospirenone may have a higher risk of dangerous blood clots.
1. Our company is a professional production leading factory in China in pharmaceutical area of many years.
Delivery areas of our products: US, UK, Canada, Australia, Brazil, Russia, Portugal, Latvia, Switzerland, Iceland, Ukraine, Germany, France, Netherlands, Belgium, Peru, Sweden, New Zealand, the Czech Republic, Lithuania, Ireland, Tunisia, Mexico, Greece, Puerto Rico, Thailand, Israel and so on.
Payment method: T/T, Western union, Moneygram, bitcoin etc.
2. Discreet package. The packing suits you best would be choosen to cross customs safely. Or if you have your own ideal way, it could be also take into consideration.
3. Top quality. High quality guarenteed, once any problem is found, the package would be reshipped for you.
4. Security Shipping: Shipping by express (FedEx, UPS, DHL, EMS), by air. The most professional forwarder would be recommanded for you.
5. We have stock, so we can delivery quickly at the very day when receive the payment.
6. Warm after-sale service for you 24/7. Any of your question would be solved for the first as soon as possible.
7. A discount would be given when you make a large order.